Our data suggest that ERK activation in responses to chemotherapeutic drugs may differ depending on the type of cancer cells, and ERK is not likely to be involved in the DUSP16-mediated resistance commonly observed in various types of cancer cells. The gene discussed is DUSP16; the disease is cancer.